Biofrontera Inc. (BFRI)
(Delayed Data from NSDQ)
$1.20 USD
+0.13 (12.15%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $1.19 -0.01 (-0.83%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BFRI 1.20 +0.13(12.15%)
Will BFRI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BFRI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BFRI
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
BFRI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know
Other News for BFRI
Biofrontera Unveils RhodoLEDĀ® XL Lamp, Eyes Market Growth
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLEDĀ® XL Lamp
Biofrontera Inc. announces launch of RhodoLED XL lamp
Biofrontera Stockholders Approve Key Governance Decisions
Analysts Offer Insights on Healthcare Companies: Biofrontera (BFRI), Gilead Sciences (GILD) and Ventyx Biosciences (VTYX)